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Objective: To examine the extent to which acute care hospitals in the Netherlands have adopted recommended
practices to prevent catheter-associated urinary tract infection (CAUTI), central line-associated bloodstream infection
(CLABSI), ventilator-associated pneumonia (VAP), and Clostridioides difficile infection (CDI).
Methods: Between 18 July 2017 and 31 October 2017, we surveyed the infection prevention teams of all acute
care hospitals in the Netherlands. The survey instrument was based on the ‘Translating Healthcare-Associated
Infection Prevention Research into Practice’ (TRIP) questionnaire and adapted to the Dutch context. Descriptive
statistics were used to examine the reported regular use of CAUTI, CLABSI, VAP, and CDI prevention practices as
well as the hospital characteristics.
Results: Out of 72 eligible hospitals, 47 (65.3%) responded. Surveillance systems for monitoring CAUTI, CLABSI, VAP,
and CDI were present in 17.8, 95.4, 26.2, and 77.3% of hospitals, respectively. Antimicrobial stewardship programs
have been established in 91.5% of participating hospitals. For CAUTI, the majority of hospitals regularly used aseptic
technique during catheter insertion (95%) and portable bladder ultrasound scanners (86.1%). Intermittent
catheterization and catheter stop-orders were regularly used by 65.8 and 62.2% of hospitals. For CLABSI, all hospitals
regularly used maximum sterile barrier precautions and chlorhexidine gluconate for insertion site antisepsis.
Avoidance of the femoral site for central line insertions was regularly used by 65.9% of hospitals. Urinary catheters
and central-lines impregnated with antibiotics or antiseptics were rarely used (≤ 5%). Selective decontamination
strategies for preventing VAP were used in 84% of hospitals. With the exception of disposable thermometers
(31.8%), all prevention practices to prevent CDI were regularly used by more than 80% of hospitals.
Conclusions: Most Dutch hospitals report regular use of recommended practices for preventing CLABSI and CDI.
Several specific practices to prevent CAUTI and VAP were less frequently used, however, providing an opportunity
for improvement.
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Healthcare-associated infection (HAI) is a serious and per-
sistent problem throughout the world. HAIs are burden-
some to patients, complicate treatment, prolong hospital
length-of-stay, induce resistance of microorganisms to anti-
microbials, raise healthcare costs, and can be life-threatening
[1–5]. In 2011, the estimated prevalence of HAIs in
European acute care hospitals was 5.7%, affecting© The Author(s). 2020 Open Access This artic
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monly reported infection types were respiratory tract
infections (23.5%), surgical site infections (19.6%),
urinary tract infections (19%), bloodstream infections
(10.7%), and gastro-intestinal infections (7.7%), of
which 48% were Clostridioides difficile infection (CDI)
[6]. Hospital surveillance in the Netherlands showed a
decreasing prevalence of HAIs from 7.2% in 2008 [7]
to 5.0% in 2017 [8]. Despite this decrease, point
prevalence of HAIs varies considerably between Dutch
hospitals, ranging from 1.5 to 6.5% [8]. The distribu-
tion of hospitals, the severity of patient case mix orle is distributed under the terms of the Creative Commons Attribution 4.0
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between the hospitals [8].
Major types of HAIs are device-associated, including
catheter-associated urinary tract infection (CAUTI),
central line-associated bloodstream infection (CLABSI),
and ventilator-associated pneumonia (VAP) [9–11]. The
Dutch surveillance data of 2017 pointed out that 17% of the
observed HAIs were symptomatic urinary tract infections -
of which 62% were catheter-associated. Primary blood-
stream infections accounted for 0.8% of the observed HAIs
of which 33% were central line-associated, and pneumonia
accounted for 20% of the observed HAIs - of which 21%
were ventilator-associated [8].
It is estimated that 65% of CAUTIs, 55% of CLABSIs,
and 55% of VAPs could be prevented by using certain
evidence-based infection prevention strategies [12, 13].
Most strategies focus on a core set of recommended pre-
vention practices, based on guidelines from numerous pro-
fessional organizations and government agencies [14–17].
The extent to which these practices are adopted by Dutch
hospitals is unknown. We thus conducted a nationwide
cross-sectional survey to evaluate the use of currently rec-
ommended practices for preventing CAUTI, CLABSI,
VAP, and CDI in the Netherlands.
Methods
Study design and survey instrument
Data for this cross-sectional study were collected using a
survey instrument based on the ‘Translating Healthcare-
Associated Infection Prevention Research into Practice’
(TRIP) questionnaire developed by Krein, Saint, and
colleagues and previously distributed in the USA, Japan,
and Thailand [18–24]. The instrument contained ques-
tions about general hospital characteristics (e.g. number
of beds), general infection prevention policies (e.g. pres-
ence of guidelines and surveillance systems), staffing of
the infection control program, and use of specific prac-
tices related to the prevention and monitoring of
CAUTI, CLABSI, VAP, and CDI. The survey instrument
was forward-backward translated into Dutch by the
research team with support of a bilingual translator and
digitalized afterwards with LimeSurvey. Some questions
were slightly modified to fit the Dutch context. These
questions mainly related to hospital characteristics, job
functions, and organizational structure. As in the ori-
ginal survey instrument, respondents were asked to indi-
cate the frequency of use for certain infection prevention
practices on a scale from 1 (never use) to 5 (always use).
The survey instrument was pilot tested by five infection
preventionists from five different hospitals, recruited via
the Dutch Association for Hygiene & Infection Preven-
tion in Healthcare, to ensure the validity, reliability, and
acceptability of the survey. No changes were made after
pilot testing (see Additional file 1).Data collection procedure
Between July 18, 2017 and October 31, 2017, we
approached 72 infection prevention teams, representing
all acute care hospitals in the Netherlands, to participate
in the survey. We first contacted infection prevention
teams by telephone to explore their willingness to par-
ticipate. An email invitation with log-in details was then
sent to the infection prevention representative of the
teams that agreed to participate. A reminder e-mail was
sent after 2 weeks to non-responders. After 4 weeks,
those who had not yet responded were contacted by
telephone. The survey responses were anonymized.
Statistical analysis
Descriptive statistics, n (%) for categorical and mean ±
standard deviation (SD) for continuous variables were
examined for all hospital characteristics as well as spe-
cific infection prevention practices. Responses about
practice use were further categorized, with responses of
4 or 5 (i.e. ‘almost always use’ or ‘always use’) defined as
regular use and coded as 1, and 0 otherwise. All statis-
tical analyses were conducted in SAS V9.4 (Cary, NC).
Results
Infection prevention teams of 47 hospitals completed
the questionnaire, yielding a response rate of 65% (47/
72). Nineteen out of the 72 hospitals declined to partici-
pate in advance, mainly because of time constraints. Of
these, three hospitals explicitly indicated that they had
not implemented specific infection prevention measures
with regard to CAUTI, CLABSI, VAP, and CDI. Of the
53 hospitals that were willing to participate in the
survey, 6 did not complete the questionnaire, despite
several reminders.
Select hospital characteristics are shown in Table 1.
The responding hospitals averaged 514.1 acute care beds
(median 481) with 21.0 Intensive Care Unit (ICU) beds
(median 12). There was an average of 4.8 infection pre-
vention personnel, with an average of 3.9 Full-Time
Equivalent (FTE) employees, at the hospitals. All respon-
dents indicated that their hospital had clear infection
prevention guidelines present that support the clinical
teams, and 91.5% indicated that all the resources and
materials for appropriate application of the guidelines
were available. An antimicrobial stewardship program
was present in 43 (91.5%) hospitals.
The presence of surveillance systems for monitoring
infection rates varied considerably by infection type. Sur-
veillance for monitoring CAUTI rates was the lowest,
with only 17.8% of hospitals with an established system.
Additionally, only 20% of hospitals had established sys-
tems to monitor urinary catheter placement and duration.
Conversely, nearly all hospitals used an established surveil-
lance system for monitoring CLABSI rates (95.4%), and
Table 1 Hospital characteristics
Characteristic n (%)/mean ± sd
Total number of acute care hospital
beds (including ICU beds)
514.1 ± 260.1
Range 140–1100
Total number of adult ICU beds 21.0 ± 18.7
Range 5–81
Percentage of multiple bed rooms 66.4 ± 22.1
Number of infection prevention
experts
4.8 ± 1.9
Number of FTE for the infection
prevention experts
3.9 ± 1.8
Number of beds per FTE of infection
prevention experts
131.2 ± 48.6
Range 48.5–291.2
Number of medical microbiologists 2.9 ± 1.9
Number of FTE for the medical
microbiologists
2.0 ± 1.9
Hospital cooperates with other
hospitals or agencies with regard to
stimulating infection prevention
30/46 (65.2%)
Clear infection-prevention guidelines
present that support caregivers
47/47 (100%)
Resources and materials available for
proper observance of the
infection-prevention guidelines
43/47 (91.5%)
Good to very good support of the
hospital management
infection-prevention policy
41/47 (87.2%)
System for monitoring the number of
patients who have urinary catheters
placed
9/45 (20.0%)
System to monitor how long the
patient has a urinary catheter
9/45 (20.0%)
Established* surveillance system for
monitoring CAUTI rates
8/45 (17.8%)
Daily check whether the presence of
a central venous catheter is still indicated
39/43 (90.7%)
Established* surveillance system for
monitoring CLABSI rates
41/43 (95.4%)
Established* surveillance system for
monitoring VAP rates
11/42 (26.2%)
Protocol for routinely testing for CDI as
soon as patients develop diarrhea
23/44 (52.3%)
Surveillance system for monitoring the
number of patients with CDI
34/44 (77.3%)
Presence of an antimicrobial
stewardship program
43/47 (91.5%)
* Case definitions and surveillance methods used are embedded within the
Dutch PREZIES network for the surveillance of hospital acquired infections and
based on the surveillance protocols of the European Centre for Disease
Prevention and Control. Abbreviations: ICU Intensive care unit, FTE Full time
equivalent, CAUTI Catheter-associated urinary tract infection, CLABSI Central
line-associated bloodstream infection, VAP Ventilator-associated pneumonia,
CDI Clostridoides difficile infection
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presence of a central venous catheter was still indicated
(90.7%). Surveillance systems for monitoring VAP rates
were present in only 26.2% of hospitals. A surveillance sys-
tem for monitoring the number of patients with CDI was
reported by 77.3% of the participating hospitals.
The regular use of Infection prevention practices spe-
cific to CAUTI, CLABSI, VAP, and CDI are displayed in
Figs. 1, 2, 3 and 4. Several CAUTI infection prevention
practices (Fig. 1) were regularly used by the majority of
responding hospitals, including: aseptic technique during
insertion (95.0%), and portable bladder ultrasound scan-
ners (86.1%). Intermittent catheterization and catheter
reminder/nurse initiated discontinuation were regularly
used by 65.8 and 62.2% of the hospitals, respectively.
Two CLABSI prevention practices (Fig. 2) were regularly
used by all responding hospitals: maximum sterile barrier
precautions and chlorhexidine gluconate for antisepsis of
the insertion site. Avoidance of the femoral site for central
line insertion was regularly used in 65.9% of responding
hospitals. Urinary catheters and central venous catheters
impregnated with antiseptics were seldomly used (5.1%),
and central venous catheters impregnated with antibiotics
were not used at all. Three VAP prevention practices
(Fig. 3:) were used regularly by more than 60% of the
responding hospitals including: semi-recumbent position-
ing (65.5%), topical and systemic antibiotics for selective
digestive tract decontamination (65.6%) and oropharyn-
geal decontamination (63.3%). Finally, all but one CDI
prevention practice (Fig. 4) were used by over 80% of
responding hospitals.
Discussion
Over the last decade, preventing HAIs has been a major
priority worldwide and in the Netherlands [25, 26].
Implementing infection prevention measures is vital to
preventing HAIs [12, 13, 27]. Knowing which recom-
mended practices are currently used and to what extent
is a starting point for the development of effective strat-
egies for improving infection prevention efforts [28].
Several important findings emerged from our nationwide
Dutch study.
First, systems for routinely monitoring CAUTI rates,
as well as the placement and the duration of urinary
catheters in hospitalized patients are only present in
approximately 20% of the hospitals, despite the link be-
tween urinary catheters and subsequent infection [29].
The number of hospitals that regularly use urinary cath-
eter reminders or stop-orders and/or nurse initiated
catheter discontinuation to prompt timely catheter re-
moval is much lower (62%) than a similar process for
CLABSI prevention involving the use of daily checks for
whether a central line is still indicated (90%). A major
difference between the prevention of CAUTI and CLABSI
Fig. 1 Reported regular use of CAUTI prevention practices
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admitted to an ICU. Implementing urinary catheter re-
minders or stop-orders hospital-wide is generally more
challenging than within a specific ward. Institutional use
of CAUTI prevention practices may be achieved through
a hospital-wide approach focused on implementing a bun-
dle of CAUTI preventive practices [30, 31].
Second, more than 90% of the hospitals monitored
CLABSI and performed a daily check whether the presence
of a central line was still indicated. This may be a reason
why we observed rare use of routine central line changes
in Dutch hospitals. In the Netherlands, monitoring of
CLABSI is facilitated by a well-established nationwide
surveillance system [32], using strict criteria for assessing
CLABSI based on the definitions from the European
Centre for Disease Control [33]. Since 2009, CLABSI inci-
dence in ICUs decreased from 4.3/1000 central line days to
1.2/1000 central line days in 2016 [34, 35]. It is likely that
the national patient safety program ‘Prevent harm, work
safely’ has contributed to this decline. A key focus of this
five-year programme (2008–2012) was on the implementa-
tion of a central-line insertion and maintenance bundle
[36]. The programme demonstrated that the compliance
rate for the bundle element ‘Daily check whether the
central line is still indicated’, increased from 60% to ≥80%
in 2014 [37]. A recent meta-analysis by Ista and colleaguesFig. 2 Reported regular use of CLABSI prevention practicesshowed that the incidence of CLABSI decreased signifi-
cantly after the implementation of central-line bundles,
from 6.4/1000 catheter days to 2.5/ 1000 catheter days
[38]. A significant proportion of patients with a central
venous catheter are admitted to an ICU, and many
CLABSI prevention practices have primarily been imple-
mented in ICUs. This is reflected in the Dutch surveillance
data of CLABSI incidence in non-ICUs. Between 2009 and
2016, only a small decrease in CLABSI incidence occurred
within non-ICUs (from 3.5/1000 line days to 3.3/1000 line
days) [34, 35]. This finding underscores the importance of
also effectively implementing CLABSI infection practices
outside of the ICU setting.
Third, VAP rates are rarely monitored by Dutch hospi-
tals. This is probably due to the ongoing debate about
which definition and criteria should be used for this
complication [39, 40]. While the diagnosis of VAP is
usually made on clinical, microbiological and radio-
logical criteria, low interrater reliability and poor correl-
ation with histopathology have been described [39, 41].
A meta-analysis of three Dutch studies on the effects of
systemic antibiotics for selective digestive tract decon-
tamination and oropharyngeal decontamination showed
that both practices reduce ICU mortality and ICU-
acquired Gram-negative bacteraemia, without increasing
antibiotic resistance [42, 43]. Based upon these findings,
Fig. 3 Reported regular use of VAP prevention practices
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tract decontamination and oropharyngeal decontamin-
ation in patients with an expected length of ICU stay of
more than 48 h was included in the Dutch antibiotic
policy guidelines. The results of our study reflect the
broad implementation of these policy guidelines. Select-
ive decontamination strategies for preventing VAP were
used in 84% of the hospitals and almost two-thirds of
Dutch hospitals reported using systemic antibiotics for
selective digestive tract decontamination and oropharyn-
geal decontamination. However, in all Dutch studies on
selective digestive tract decontamination in the ICU,
evaluation of VAP was performed in a research setting
[43]. The remaining VAP prevention practices were only
moderately implemented, perhaps as a result of the
focus on selective decontamination strategies.
Fourth, infection prevention practices and surveillance sys-
tems for monitoring CDI are highly implemented in Dutch
hospitals. Soon after CDI outbreaks in the Netherlands in
2005, a national surveillance program for CDI was initiated
to rapidly recognize CDI and prevent further spread [44].
Simultaneously, a nationwide multi-modal approach was in-
troduced to prevent CDI, recommending: (a) restricted use
of antibiotics; (b) strict enteric precautions when lookingFig. 4 Reported regular use of CDI prevention practicesafter patients with diarrhea; and (c) meticulous cleaning of
clinical areas [45]. The well-implemented CDI prevention
practices found in this study are therefore in line with our
expectations.
Fifth, our data show that hospital-wide antimicrobial
stewardship programs have been established in nearly all
of the respondent hospitals (91%), corresponding with
the findings of Kallen and colleagues on the current
state of antimicrobial stewardship in Dutch hospitals
[46]. Since 2014, it is mandatory for each hospital in the
Netherlands to have an antimicrobial stewardship team,
with the task of monitoring the quality of the antibiotic
use in their hospital.
Finally, urinary catheters and central venous catheters
impregnated with antibiotics or antiseptics are seldom
used in the Netherlands. The Netherlands Society of
Intensive Care does not advocate for using antimicrobial
catheters, based on a recent review concluding that
beneficial effects of catheter impregnation on relevant
patient outcomes such as clinical sepsis and mortality
have not been demonstrated [47].
Our findings should be interpreted in the context of
several limitations. First, our response rate was less than
100% and the non-response could have biased our
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responding hospitals were comparable to those of the 47
hospitals (65%) that participated in our study. We there-
fore believe that our results generally reflect the use of
infection prevention practices by Dutch hospitals. Sec-
ond, we used self-reported data of infection control pro-
fessionals. Our findings on some infection prevention
practices could be inaccurate if the respondent was not
sufficiently aware of all actual practices. An individual
respondent may have overestimated or underestimated
how frequently the various practices were used [48].
However, we have thoroughly instructed respondents -
both verbally and in writing - to consult a colleague if
certain infection prevention practices were beyond their
scope of attention. We therefore have no reason to
believe that systematic inaccuracies have occurred. Still,
we cannot rule out potential response bias (e.g. recall,
social-desirability) and acknowledge that respondent
answers may not correlate perfectly with the actual day-
to-day reality of their respective hospital. Third, as our
intent was to present a cross-sectional snapshot of infec-
tion prevention in Dutch hospitals, our analyses are
limited to univariate analyses. As a consequence, infer-
ences regarding the determinants of regular use of the
infection prevention practices are not provided. Finally,
although we collected a considerable amount of infor-
mation about the use of infection prevention practices,
we do not have data on actual infection rates. As a
consequence we were not able to present relationships
between the use of the various infection prevention
practices and infection outcomes. Nevertheless, research
has shown that most of the infection prevention prac-
tices included in our study contribute substantially to
reducing HAIs; such practices are generally included in
published national and international guidelines.
Conclusion
Our study is, to our knowledge, the first national assess-
ment of HAI prevention practices in the Netherlands.
Although many Dutch acute care hospitals are using
most of recommended HAI prevention practices, there
is currently wide variation among Dutch hospitals in the
use of practices focused on preventing CAUTI and VAP.
To further improve the adoption of key infection pre-
vention practices among Dutch hospitals, hospital-wide
implementation strategies - informed by known barriers
and facilitators - are needed. These strategies could
include engaging in large-scale collaborative networks
that focus attention on HAI prevention and provide
guidance and implementation tools to hospitals that
may be struggling [49]. Given the success of such
collaborative efforts to prevent CLABSI and CDI in
Dutch hospitals, we anticipate that similar efforts to
prevent CAUTI and VAP will also be successful.Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13756-019-0667-3.
Additional file 1. TRIP Dutch questionnaire.
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